SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-209778
Filing Date
2019-08-01
Accepted
2019-08-01 07:46:02
Documents
5
Period of Report
2019-08-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d779938d8k.htm 8-K 19942
2 EX-99.1 d779938dex991.htm EX-99.1 55462
3 GRAPHIC g779938page5a.jpg GRAPHIC 3829
4 GRAPHIC g779938page5b.jpg GRAPHIC 7125
5 GRAPHIC g779938page5c.jpg GRAPHIC 1674
  Complete submission text file 0001193125-19-209778.txt   94373
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 19990980
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences